Hot Products

Tanshindiol B
Catalog No: CFN92146

Tanshindiol B possesses a unique anti-cancer activity whose mechanism involves the inhibition of EZH2 activity and would provide chemically valuable information for designing a new class of potent EZH2 inhibitors. It also possesses the anti-angiogenic activity,so it can be a promising candidate for angiogenesis inhibitors.

Tanshindiol C
Catalog No: CFN92147

Tanshindiol C protects macrophages from oxLDL induced foam cell formation via activation of Prdx1/ABCA1 signaling and that Prdx1 may be a novel target for therapeutic intervention of atherosclerosis.It possesses a unique anti-cancer activity whose mechanism involves the inhibition of EZH2 activity and would provide chemically valuable information for designing a new class of potent EZH2 inhibitors.

Tanshinlactone
Catalog No: CFN99072

Standard reference

Tanshinol B
Catalog No: CFN90370

Reference standards.

Tanshinone I
Catalog No: CFN98953

Tanshinone I is an inhibitor of type IIA human recombinant sPLA2 (IC50=11 μM) and rabbit recombinant cPLA2 (IC50=82 μM). Tanshinone I possesses hepatocyte protective, anticancer, neuroprotection, and nephroprotective properties. Tanshinone I pretreatment causes significant suppression of skin cell death induces by solar simulated UV and riboflavin-sensitized UVA.

Tanshinone IIA
Catalog No: CFN98952

Tanshinone IIA is an estrogen receptor partial agonist with antiandrogenic properties, it has neuroprotective effects against cerebral ischemia/reperfusion injury and traumatic injury of the spinal cord in rats. Tanshinone IIA has anti-leukemia, anti-inflammatory and anti-oxidative properties, inhibits the release of inflammatory cytokines, such as, IL-1 β, IL-6 α, TNF-α.

Tanshinone IIA-sulfonic sodium
Catalog No: CFN90399

Tanshinone IIA sulfonate (sodium) is a water-soluble derivative of tanshinone IIA, which acts as an inhibitor of store-operated Ca2+ entry (SOCE), and is used to treat cardiovascular disorders.Sodium tanshinone IIA sulfonate pretreatment reduces infarct size and improves cardiac function in an ischemia-reperfusion-induced rat myocardial injury model via activation of Akt/FOXO3A/Bim-mediated signal pathway.

Tanshinone IIB
Catalog No: CFN99820

Co-treatment with Tanshinone IIB (TSB) significantly inhibits the DNA laddering, cytotoxicity and apoptosis of rat cortical neurons induced by staurosporine in a concentration-dependent manner; TSB also suppresses the elevated Bax protein and decreased bcl-2 and caspase-3 proteins induced by staurosporine in rat cortical neurons; TSB is effective in reducing stroke-induced brain damage and may represent a novel drug candidate for further development. TSB significantly inhibits the uptake of digoxin and vinblastine in membrane vesicles containing PgP or MRP1, moderately stimulates PgP ATPase activity, suggesting TSB is a substrate for PgP and MRP1 and that drug resistance to TSB therapy and drug interactions may occur through PgP and MRP1 modulation.

Tarasaponin VII
Catalog No: CFN90543

Reference standards.

Taraxasterol
Catalog No: CFN99074

Taraxasterol has anti-inflammatory, anti- tumor-promoting , anti-endotoxic shock and anti-allergic asthma activities. It inhibited NO, IFN-γ, PGE(2), TNF-α, IL-1β and IL-6 production.